Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CAD | P27708 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6315164 | 0.83 | MGAM (0.42) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL13108403 | 0.83 | MGAM (0.42) | MGAMGAASIMGAM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6315156 | 0.81 | MGAM (0.41) | MGAMGAASIMGAM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL19948891 | 0.81 | MGAM (0.41) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL31251996 | 0.78 | MGAM (0.42) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL17452136 | 0.78 | MGAM (0.42) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL23844118 | 0.77 | MGAM (0.41) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL28211824 | 0.77 | ALOX15 (0.41) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL7601776 | 0.77 | MGAM (0.41) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL5812119 | 0.75 | ALDH1A1 (0.42) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720072-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260078133-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2026-03-19 | — | — | US | disclosed |
| WO-2024249299-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078133-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | MGAM 4595/4885GAA 3614/4885SI 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.